Department of Otolaryngology, Head and Surgery, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Center for Sleep Medicine, Department of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Neurotherapeutics. 2021 Jan;18(1):91-99. doi: 10.1007/s13311-021-01012-x. Epub 2021 Feb 8.
Hypoglossal nerve stimulation (HGNS) therapy was approved in 2014 for the treatment of obstructive sleep apnea in patients who are intolerant to continuous positive airway pressure (CPAP) therapy, which is reported in up to 40-60% of patients. This therapy works via direct neurostimulation of the hypoglossal nerve in synchrony with respiration, to open the airway via tongue stiffening and protrusion. Studies have demonstrated significant reductions in both respiratory parameters such as disordered breathing indices, as well as subjective sleep complaints, such as daytime sleepiness, with the use of this therapy. This has increased the repertoire of treatment options for sleep providers to recommend to those patients that are intolerant to CPAP therapy.
舌下神经刺激（HGNS）疗法于 2014 年获得批准，用于治疗对持续气道正压通气（CPAP）治疗不耐受的阻塞性睡眠呼吸暂停患者，据报道，多达 40-60%的患者对此不耐受。该疗法通过与呼吸同步直接对舌下神经进行神经刺激，通过舌僵硬和突出来打开气道。研究表明，这种治疗方法可显著降低呼吸参数，如呼吸紊乱指数，以及主观睡眠抱怨，如白天嗜睡。这增加了睡眠提供者向对 CPAP 治疗不耐受的患者推荐的治疗方案选择。
